# Umur Hursever

> Umur Hursever is a Series C investor at Lightrock (London) backing Medical and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Lightrock](https://shizune.co/investors/profile/lightrock)
- Location: London, United Kingdom
- Total investments: 6
- Last investment: Jul 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/umur-hursever-a50179/?originalSubdomain=uk

Umur Hursever is a Series C investor at Lightrock in London focused on Medical and Health Care. Umur Hursever is Partner at Lightrock

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Robotics | 1 | 17% |
| Software | 1 | 17% |
| Medical Device | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Series D | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ultromics | Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. | $55M | Series C | Jul 31, 2025 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $163.9M | Series D | Sep 20, 2023 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $600M | Series D | Jun 28, 2021 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $240M | Series C | Sep 17, 2019 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $96.9M | Series B | Jun 04, 2018 |  |
| CMR Surgical | CMR Surgical develops and manufactures robotic surgical systems designed to enhance precision and efficiency in minimally invasive surgery. Its primary product, Versius, is a versatile and modular robotic system that supports various surgical procedures.Versius is designed to mimic the human arm's flexibility while offering a compact andergonomic design. It integrates with hospital workflows and provides data-driven insights to support surgical performance. CMR Surgical collaborates with healthcare professionals to ensure that its technology meets clinical needs and improves patient outcomes. | $26M | Series A | Sep 18, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 5 deals together
- [Watrium AS](https://shizune.co/investors/profile/watrium-as) — VC Fund, 4 deals together
- [Escala Capital](https://shizune.co/investors/profile/escala-capital) — VC Fund, 3 deals together
- [Lightrock](https://shizune.co/investors/profile/lgt-lightstone) — VC Fund, 3 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [Lightrock](https://shizune.co/investors/profile/lightrock) — VC Fund, 2 deals together

## About Lightrock

VC Fund · London, United Kingdom

Lightrock is a global growth capital platform that backs purpose-driven entrepreneurs tackling the world’s biggest challenges. Lightrock invests in companies that pursue scalable and tech-driven business models around the key impact themes of people, planet, and productivity/tech for good. Lightrock’s portfolio includes more than 90high-growth companies across Europe, US, Latin America, India and Africa, supported by more than 100 Lightrock professionals based in 6 global offices. Lightrock is backed by LGT, the international private banking and asset management group, and other leading global institutions.For more information, please visit www.lightrock.com.

5 contacts available at Lightrock.

| Name | Title | Profile |
| --- | --- | --- |
| Christopher Steinau | Growth Investor | https://shizune.co/investors/profile/christopher-steinau |
| Kevin Bone | Partner | https://shizune.co/investors/profile/kevin-bone-27a9 |
| Marcos Wilson Pereira | Partner, Head of Latin America | https://shizune.co/investors/profile/marcos-pereira |
| Pal Erik Sjatil | Global Managing Partner and CEO | https://shizune.co/investors/profile/pal-erik-sjatil |
| Umur Hursever | Partner | https://shizune.co/investors/profile/umur-hursever |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Umur Hursever invest in?

Umur Hursever invests primarily in Medical, Health Care and Robotics startups, most often at Series C and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Umur Hursever last invest?

The most recent investment recorded for Umur Hursever closed in Jul 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co